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Abstract
Regulatory T cells (Tregs) suppress immune responses against both self and non-self antigens. Tregs require activation
through the T cell receptor (TCR) and IL-2 to exert their suppressive functions. However, how strength of TCR signals
modulate the potency of Treg-mediated suppression of antigen-specific T cell activation remain unclear. We found that
both strength of TCR signals and ratios of Tregs to target cells, either through superantigen, allogeneic antigens or HIV-
specific peptides, modified the suppressive ability of Tregs. While human Tregs were able to mediate suppression in the
presence of only autologous antigen-presenting cells, this was much less efficient as compared to when Tregs were
activated by allogeneic dendritic cells. In another physiologically relevant system, we show that the strength of peptide
stimulation, high frequency of responder CD8+ T cells or presence of high IL-2 can override the suppression of HIV-specific
CD8+ T cells by Tregs. These findings suggest that ratios and TCR activation of human Tregs, are important parameters to
overcome robust immune responses to pathogens or allogeneic antigens. Modulating the strength of T cell signals and
selective enhancement or depletion of antigen-specific Tregs thus may have implications for designing potent vaccines and
regulating immune responses during allogeneic transplantation and chronic infections.
Citation: Antons AK, Wang R, Kalams SA, Unutmaz D (2008) Suppression of HIV-Specific and Allogeneic T Cell Activation by Human Regulatory T Cells Is
Dependent on the Strength of Signals. PLoS ONE 3(8): e2952. doi:10.1371/journal.pone.0002952
Editor: Douglas F. Nixon, University of California San Francisco, United States of America
Received July 8, 2008; Accepted July 21, 2008; Published August 13, 2008
Copyright:  2008 Antons et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health Grant R01 AI065303 to DU and R01 grant AI39966, Vanderbilt-Meharry Center for AIDS
Research (P30 AI54999), Elizabeth Glaser Pediatric AIDS Foundation to SAK. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Derya.Unutmaz@nyumc.org
Introduction
The role of regulatory T cells (Tregs) in maintaining control of
immune responses in the context of autoimmunity, transplantation
and infectious diseases is now well-established. Tregs are CD4
+ T
cells which express the transcription factor FoxP3. Phenotypically,
human Tregs constitutively express high levels of CD25, and the
memory marker CD45RO, various activation markers [1] and lack
the expression of IL-7 receptor, CD127 [2,3]. Tregs are
hyporesponsive to TCR stimulation, as displayed by their impaired
proliferative capacity and cytokine secretion upon stimulation in
vitro [1,4]. Tregs require activation through the T cell receptor
(TCR) [5] and cell-to-cell contact for suppression [6,7]. Loss of
Tregs or lack of Treg function in vivo results in severe autoimmune
disorders in humans and mouse models [8,9,10].
A favored model of Treg differentiation proposes that a
population of thymocytes that recognize self-MHC/antigen com-
plexes, escape negative selection and enter the FoxP3
+ Treg
differentiation pathway [11,12,13,14]. However, a recent study that
characterized hundreds of TCRs expressed by FoxP3- naı ¨ve CD4
+
T cells, or Tregs showed that non-self-antigens are the cognate
specificities of FoxP3+ Tregs [15]. In support of the notion that
Tregs recognize antigensother than self, several reportsshowedthat
Tregs recognize exogenous microbial antigens derived from viral
[16,17,18,19,20], bacterial, fungal [21,22,23,24,25] and parasitic
origins [25,26,27], as well as allogeneic tissues during transplanta-
tion [28,29]. It has been unclear whether these Treg responses are
antigen-specific or rely on inherent cross reactivity, or are bystander
activations with self-antigen.
Conflicting results in numerous model systems in identifying the
specificity of the antigen during suppression have made it difficult
to identify precise parameters and mechanisms of Treg-mediated
suppression [15]. Transwell experiments have shown that direct
cell contact between Tregs and target cells is required [6,7], or that
they secrete inhibitory soluble mediators that act at very close
proximity of target cells. IL-2 is also involved in the development
and function of Tregs [30,31,32,33]. IL-2 signaling appears to be
required for both the thymic development and peripheral
expansion/maintenance of Tregs [31,32,33]. How IL-2 is involved
in T cell function remains controversial. Tregs from mice
containing a FoxP3 knock-in-allele engineered to lack IL-2 or
the IL-2a chain were both capable of suppressing T cell
proliferation in vitro [31]. In contrast, it has been shown that
suppression is completely abrogated by selective blocking of the
IL-2 receptor on the Tregs [30].
Understanding the mechanisms of Treg-mediated suppression
could be important in controlling a variety of disease processes.
For example by enhancing Tregs during transplantation, it may be
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important in controlling the immune response during chronic
infections [1,34,35] or conversely unwanted or aberrant Treg
function may result in inefficient responses to infectious diseases
[35,36]. Of particular interest is HIV infection, which has the
hallmark of chronic immune activation [37,38]. We and others
have shown that Tregs are targeted by HIV and are depleted
during late stages of the disease, potentially contributing to hyper-
activation [1,36]. It has also been shown that Tregs can blunt
immune responses against HIV infection in vitro [17,39] as well as
other infectious diseases [21,25,40]. However, it is not yet clear
how efficiently Tregs can suppress HIV-specific immune responses
in vivo or whether they can directly recognize HIV antigens.
Therefore, understanding the mechanisms of Tregs during HIV
and other chronic viral infections [41], is critical to develop better
preventive and therapeutic vaccine approaches.
We sought to better understand the relationship between the
strength of TCR signals and ability of Tregs to suppress immune
activation in three different in vitro antigen-specific models: 1)
Superantigen, 2) Allogeneic and 3) HIV-specific peptides. We
show that the efficiency of human Treg-mediated suppression is
strongly dependent on the magnitude of antigen-specific signals
directed towards both the target and Tregs in all three in vitro
models. We also found that increasing the ratios of Tregs to target
cells, partly overcomes stronger TCR signals. These findings
underscore the intricate balance between Tregs and effector cells
in generating, maintaining and suppressing immune responses.
Results
Strength of TCR activation and Treg numbers modulate
the level of Treg mediated suppression
In in vitro assays, ratios of Tregs to target cells that are between
1:1 to 1:4 are typically used for suppression of T cell activation
[1,6,7,42]. Treg mediated suppression is also dependent on the
strength of TCR activation and is more potent at suboptimal levels
of activation [6,7]. We further investigated how the the strength of
TCR signals and Treg ratios affected suppression of T cell
activation. Tregs and naı ¨ve CD4
+ T cells (TN) were purified from
healthy human peripheral blood. Target CD4
+ T cells were labeled
with CFSE. These cells were then activated with dendritic cells
(DCs) pulsed with different concentrations of a superantigen (SEB),
either in the presence of non-labeled control memory CD4+ T cells
(TM) or Tregs. As expected, a 1:1 ratio of Treg to target cell yielded
efficient suppression of T cell activation (Figure 1). Increasing the
concentration of SEB by 10-fold reduced the efficiency of Treg-
mediated suppression at 1:1 ratio of Tregs to target cells (Figure 1).
However, when Tregs to Target ratio was increased to 3:1 ratio
Tregs were also capable of suppressing 10-fold higher SEB
concentrations (Figure 1). Whereas, addition of IL-2 to the cultures
greatly reduced the effectiveness of Tregs to suppress T cell
activation even at high ratio of Treg to target cells (Figure 1).
Suppression of allogeneic and auto-antigen mediated T
cell activation by Tregs
Tregs could play an important role in controlling graft-versus-
host-disease (GVHD) during allogeneic transplantations. It is not
clear whether recognition of allo-antigens by Tregs render them
more potent in their suppressive capacity as compared to Tregs that
recognize autologous antigens. Based on our previous findings we
hypothesized that suppression of allo-specific immune responses
would be more efficiently mediated by Tregs activated by allogeneic
compared to autologous DCs. To test this we devised an in vitro
suppression assay, whereby we purified both TN and Tregs from the
peripheral blood of 8 different human subjects. We also generated
DCs from each of these donors as described [43]. We next set up
matched experiments to mix with CFSE labeled TN cells with Tregs
and DCs in either of these conditions: 1) Allogeneic vs. allogeneic:
both Tregs and TN cells were from the same donor and stimulated
with allogeneic DCs from another donor. 2) Autologous vs.
autologous: both Tregs and TN cells were from the same donor
stimulated with autologous DCs. 3) Autologous vs. allogeneic: TN
cells from one donor were stimulated with the same donor
autologous DCs, in the presence of Tregs from a different donor
therefore recognizing DCs as allogeneic. 4) Allogeneic vs.
autologous: TN cells from a donor were stimulated with DCs from
a different donor, in presence of Tregs that were isolated from the
same donor as the DCs (Figure 2A).
We observed that allogeneic Tregs were very potent in
suppressing activation of both autologous and allo-specific CD4
+
T cell proliferation (Figure 2B). Autologous Tregs were also
relatively efficient in suppressing CD4+ T cell proliferation in
response to presumably self-antigens presented by autologous DCs
(Figure 2B). However, when both DCs and Tregs were from the
same donor, these Tregs were much less efficient in suppressing
allogeneic CD4+ T cell activation (Figure 2B). In summary these
results show that while Tregs that potentially recognize self-
antigens are capable of suppressing self-antigen mediated T cell
proliferation, they are less effective when responder T cells are
activated by allogeneic stimuli. In contrast, when Tregs recognize
allo-antigens they become more potent suppressors. Taken
together these findings suggest that self-reactive Tregs are not as
potently activated as allogeneic antigens and that this strength of
signal is a critical parameter in efficient Treg-mediated suppres-
sion.
Figure 1. Strength of TCR activation and Treg numbers
modulates level of suppression. CD4+ naı ¨ve T cells were isolated
and CFSE labeled. Unlabeled control TM or Tregs were added to the
cultures at the target to Treg ratio as indicated. Cells were stimulated
with 2 different concentrations of SEB, or in the presence of IL-2. Shown
is percent suppression by the Tregs when normalized to TM or TN
control. The % suppression on Y-axis is calculated as follows: We first
determined the percent of CFSE labeled target cells dividing in
response to the stimuli alone. We then determined the proliferative
percentage of cells in the presence of Tregs or control effector T cells.
The percent suppression was then calculated by percent reduction in
proliferation of the target cells in the presence of effectors as compared
to target cells alone. As an example, in one experiment 40% of the CFSE
labeled T cells divided in response to SEB stimulation. In the presence of
Tregs the same cells divided only 4%. Thus, we represent this as 90%
suppression. Data shown are representative of three replicate
experiments.
doi:10.1371/journal.pone.0002952.g001
Parameters of Treg Suppression
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or allogeneic Tregs
We next sought to recapitulate the previous findings in a
physiological immune response model, where a defined antigen-
specific activation can be precisely controlled. We utilized a cohort
of HIV+ individuals who are considered HIV+ slow-progressors as
defined by viral loads of less than 50,000 copies/ml in the absence
of antiviral therapy that have been well characterized in respect to
their HIV-specific immune responses. The viral and immunolog-
ical profiles of the infected individuals are shown in Table 1.
PBMC from HIV+ individuals were labeled with CFSE and
stimulated with HIV peptide (HLA-B57 restricted), KAFSPE-
VIPMF (KF11) in the presence or absence of Tregs or CD4+ T
cell subsets from an HIV negative subject. We then assessed the
proliferation of the KF11-specific CD8 responses, after 5 days, by
co-staining with HLA-class I tetramers pulsed with KF11 peptides,
Figure 2. Treg mediated suppression of allogeneic T cell responses. (A) Experimental setup allogeneic vs. autologous stimulation of CFSE
labeled target cells (TN), and Tregs. (B) Conditions were designed as depicted in Figure 2A. Shown is percent suppression by the Tregs normalized to
control T cells. Each point represents an individual experiment. in total 8 experiments separate experiments were performed. P values are shown
above the brackets as calculated by Student’s t Test.
doi:10.1371/journal.pone.0002952.g002
Parameters of Treg Suppression
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Tregs were very efficient in suppressing the proliferation of CD8+
HIV specific immune responses at suboptimal peptide concentra-
tions (Figure 3B). However, suppression was much less efficient
when the concentration of KF11 peptide was increased 10-fold
(Figure 3B). At lower ratios of Tregs to HIV specific CD8
+ cells the
Tregs could not fully suppress proliferation of KF11-specific T
cells (Figure 4A). Addition of IL-2 to PBMCs stimulated with HIV
specific peptide also affected the ability of allogeneic Tregs to
suppress the proliferation of a HIV specific response (Figure 4B), in
agreement with our previous result (Figure 1).
To determine whether autologous Tregs from PBMCs of HIV
controllers can also have suppressive function against HIV-specific
CD8
+ T cells, we depleted CD25
+ Tregs from the PBMC of these
individuals and tested their responses to peptide stimulation.
Similar to above experiments CD25
+ T cell depleted PBMC were
labeled with CFSE and HIV-specific CD8+ cells were identified by
directed staining with KF11-tetramer, and proliferation was
assessed 5 days post-stimulation. We did not observe any
significant enhancement of CD8
+ T cell proliferation in any of
the donors tested with wide range of peptide concentrations when
Tregs were depleted from PBMCs (Figure 5A). Similar results
were obtained when CD8+ T cells were stimulated with Gag
peptide pools (data not shown). In addition, when we added back
the sorted autologous CD25
+ cells into these activation cultures at
high ratios compared to responder CD8+ T cells (5:1) there was
still no suppression of HIV-specific proliferation (Figure 5A).
One possibility for inability of autologous Tregs isolated from
HIV-infected donors could be that these cells have lost their
suppressive capacity. In order to rule out this possibility we tested
their capability to suppress CD4
+ T cell activation in a
superantigen-mediated activation system described in Figure 1.
We found that Tregs isolated from HIV+ donors were equally
functional in their suppressive ability (Figure 5B). Together, these
findings suggest that in these HIV-infected subjects, activation of
Tregs by presumptive self-antigens only is not sufficient to suppress
HIV-specific CD8+ T cell activation.
Discussion
In this study, we found that the activation signals to the target T
cells and Tregs can modulate the suppressive function of the
Tregs. Increasing the strength of signal or presence of IL-2 can
override the Treg-mediated suppression, which we show in the
context of three different in vitro models of antigen-specific T cell
activation. In contrast, higher frequency of Tregs and stronger
stimuli through their TCR results in better suppression of effector
T cell activation, The data presented here provides us with better
insight into the delicate balance between activation signals and
suppressing an antigen specific response.
We showed that the strength of TCR and IL-2 signals affects the
magnitude of suppression that can be achieved by the Tregs.
However, it remains to be determined whether direct suppression
of initial activation of antigen-specific T cells by Tregs extinguishes
the immune response at a population level of T cells, without
directly inhibiting every responder T cell. This could potentially
happen in a scenario where Tregs stop few potent responder T
cells from secretion of cytokines, thus limiting the availability of
growth factors such as IL-2 to neighboring cells that may require
IL-2 for efficient activation. Indeed, addition of IL-2 to in vitro
activation cultures overrides Treg-mediated suppression of target
T cells during both SEB and allogeneic stimulation. It is also
possible that IL-2 changes the activation threshold needed for
Treg suppressive capability at the cell-to-cell interaction level.
While not mutually exclusive, these data highlight the important
double-edged role of IL-2 both in enabling Tregs to suppress and
target cells to escape Treg-suppression.
When we stimulated Tregs only in the presence of autologous
APCs the suppression observed was less potent compared to
suppression by Tregs stimulated with SEB, allogeneic DCs or
HIV-peptide. These findings would predict that during the course
of an immune response, Tregs that recognize antigens from
pathogens develop in parallel to conventional effector/memory T
cells. In support of this prediction, we recently provided evidence
that Tregs can develop from a naı ¨ve T cell precursor when
activated in vitro through their TCR [44]. Our findings do not
rule out the possibility that autologous or bystander Treg
activation play a role in the suppression of HIV specific immune
responses. However, we speculate that suppression of HIV-specific
activation by Tregs recognizing self-antigens would not be efficient
unless HIV-specific CD8 cells are at very low frequencies.
During HIV infection, global control of T cell activation by
Tregs could conceivably limit cellular targets of HIV, as T cell
activation is required for a successful infection [16]. In contrast, it
has been suggested that HIV-immune dysfunction is associated
with suppression of HIV-specific effectors by Tregs, leading to an
inefficient immune response against HIV [36,39,45,46]. Several
reports have shown that depletion of Tregs can amplify CD8
+ T
cell responses [17,46]. One plausible reason why in our
experimental system we did not observe similar results could be
that the patient population we used has very potent and high
frequencies of CD8
+ T cell responses, thus as we showed,
rendering them more difficult to suppress. It is also possible that
the affinity of CD8+ T cells for this HIV peptide is too strong for
autologous Tregs to overcome. Indeed, increasing the dose of
peptide concentration by 10-fold was able to overcome the
suppression mediated even by the allogeneic Tregs. Further, in our
system, it is also highly unlikely that Tregs are activated by CD8+
specific HIV-peptide, therefore they would have to rely on self-
antigens in order to be activated and display their suppressive
function. In other experimental systems, where T cells are
Table 1. Immunological characteristics of HIV subjects.
Patient # Infection (years) CD4 Count CD8 Count Viral Load %FoxP3+CD4+ % KF11+ CD8
1 16 661 409 215 1.22 2.9
2 11 950 437 5917 1.81 10.1
3 15 743 414 50 1.27 1.98
4 8 700 1500 21339 0.77 9.85
5 3 1353 858 3288 1.44 9.78
doi:10.1371/journal.pone.0002952.t001
Parameters of Treg Suppression
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also potentially recognize HIV antigens and thus conceivably
more potent in suppressing HIV-specific activation.
Defining the determinants of Treg-mediated regulation of
allogeneic immune responses is essential for therapeutic applica-
tion of Tregs in transplantation tolerance and control of GVHD
[28,29,47,48]. We have confirmed that allogeneic stimulation of
Tregs renders them capable of suppressing the activation and
proliferation of conventional T cells. In order to successfully
prevent GVHD after an allograft-transplant, donor Tregs that are
transferred or develop in the host should be able to suppress most
of allo-specific CD4+ and CD8+ T cells [28]. However, our data
suggest that Tregs do not necessarily have to recognize the same
allo-antigens as the effector T cells. Successful inhibition of allo-
specific T cell activation would only require that some Tregs are
also activated at the same time, even if through different antigens.
Based on these postulates, a potential treatment approach would
be to isolate Tregs from donor blood prior to the transplantation,
which would then be activated and expanded with allogeneic DCs
from the host recipient. These Tregs can then be infused to
patients with the transplant. Because Tregs have limited in vitro
expansion potential [49,50], recently identified naı ¨ve Tregs, which
have greater proliferative capacity could be useful for this
approach [44,51,52,53].
In summary, our results indicate that the strength of TCR
signals and IL-2 can override Treg-mediated suppression when
Treg numbers and activation are limiting. In the context of HIV,
both controlling immune activation and generation of effective
Figure 3. Allogeneic Tregs are capable of suppressing antigen specific proliferation. (A) To identify HIV-peptide specific CD8+ T cells
PBMC cultures were stained with antibodies for CD3, CD4, CD8, and tetramer specific for HIV peptide, KF11. Plots shown are gated on CD3+ T cells,
and tetramer positive cells were also CD8+. (B) Tregs or control T cells were isolated from HIV-negative individuals. PBMC from HIV+ individuals were
CFSE labeled and mixed with either HIV-negative allogeneic T or Tregs, and stimulated with 0.2 or 2 ng/ml KF11 HIV peptide. Cells were stained with
KF11 Tetramer, and level of proliferation was assessed d5 post activation. Shown is percent suppression by Tregs as described in Figure 1. Data is
representative of 5 separate experiments.
doi:10.1371/journal.pone.0002952.g003
Parameters of Treg Suppression
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Treg responses during HIV infection may require fine-tuning
depending on the stage of the disease. Approaches to modulate this
delicate balance will be important when designing vaccines for
HIV or other infectious diseases and controlling the immune
response during transplantation or in chronic immune activation.
Materials and Methods
HIV donors
HIV-positive subjects were recruited through the Comprehen-
sive Care Center (Nashville, TN) and all subjects were HLA class I
typed (4 digit resolution) (DCI, Nashville, TN). All subjects were
antiretroviral naı ¨ve at the time of study with a range of CD4+ T
cell numbers from 144 to 1260/mm
3 and log viral load
measurements from 1.7 to 4.25 copies/ml. This study was
approved by the Vanderbilt University Medical Institutional
Review Board and all subjects provided written informed consent.
Cell Isolation and culture
The blood obtained from healthy donors for this study have
been reviewed and approved by Vanderbilt and NYU School of
Medicine IRB committees. PBMC were isolated from blood of
donors through Ficoll-Hypaque (Pharmacia). Resting CD4
+ T
cells were purified using CD4
+ dynabeads (Dynal) as previously
described [54] and were at least 99.5% pure as determined by
post-purification FACS analysis. To purify TN,T M, Treg and
TNreg subsets, purified CD4
+ cells were stained with CD25 and
CD45RO antibodies and CD45RO
2CD25
2 (TN) and
CD45RO
+CD25
hi (Treg) were sorted on a FACS Aria
TM flow
cytometer. The culture media used in all experiments was RPMI
(Life Technologies) and was prepared as described [54]. All
cytokines were purchased from R&D Systems. Monocyte-derived
dendritic cells (DCs) were generated as described [54].
FACS Analysis
T cells were stained with the relevant antibody on ice for 30 min
in PBS buffer containing 2% FCS and 0.1% sodium azide. Cells
were then washed twice, fixed with 1% paraformaldehyde, and
analyzed with a FACSCaliburH or FACSAriaH flow cytometer.
Figure 4. Cell ratios and IL-2 effect Treg suppression of HIV
specific proliferation. (A) Tregs or control TN cells were isolated from
HIV-negative individuals. PBMC from HIV+ were CFSE labeled and
stimulated as indicated in Figure 3B. Tregs or control T cells were added
at the ratio indicated. Shown is percent suppression by Tregs as
described (Figure 1 legend). (B) HIV-positive PBMC was stimulated with
KF11 peptide for 5 days in the presence of allogeneic Tregs and
increasing concentrations of IL-2. Data is representative of three
separate experiments.
doi:10.1371/journal.pone.0002952.g004
Figure 5. Depletion of Tregs does not result in increased KF11-
specific proliferation. (A) PBMC from HIV+ individuals were stained
with antibodies directed against CD4 and CD25. CD4+CD25
hi cells were
removed from the PBMC by sorting CD4+CD25
hi T cells using FACS.
Total or CD4
+CD25
hi depleted, or PBMC were then CFSE labeled and
stimulated with KF11 peptide. Cells were stained as in Figure 3A, and
percentage of KF11-specific CD8
+ T cells that proliferated is shown for 3
representative donors. In conditions that CD4
+CD25
hi cells were added
back to cultures, they were added at a ratio of at least 3:1 CD4
+CD25
hi
to labeled PBMC. (B) Treg, TN or TM cells were isolated from purified
CD4
+ T cells from HIV+ individual, based on expression of CD45RO and
CD25. TN cells from the same donor were CFSE labeled, and unlabeled
TN,T M or Tregs were added at a ratio of 1:1 target to effector T cells.
Cultures were stimulated with SEB pulsed DCs, and fixed on day 4–5
post activation. Histogram of CFSE labeled target cells are displayed,
and the percentage of cells that have proliferated as shown in gates.
Representative is one out of three experiments.
doi:10.1371/journal.pone.0002952.g005
Parameters of Treg Suppression
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and analysis was performed using FlowJo software (Tree Star).
Antibodies used in experiments were: CD4-APC Cy7, CD8-PB,
CD3-PE Cy7, CD14-PerCP, CD19-PerCP, CD56-PE Cy5.5 (All
from BD Pharmigen) and B57-KF11 Tetramer-PE (Beckman
Coulter).
T cell suppression Assay
Purified CD4
+ T cells were FACS sorted, as described above,
based on expression of CD25 and CD45RO. Target PBMC
(peptide stimulated suppressions) TN or TM (SEB stimulated
suppression) cells were CFSE labeled. Purified cells were first
washed and resuspended in (PBS). While vortexing the cells, CFSE
was added at a final concentration of 5 mM. The mixture was
vortexed for an additional 15 s and incubated at 37uC for 3 min.
Labeling was quenched by addition of 50% fetal calf serum in
PBS. Cells were washed once more with 50% serum PBS, followed
by two washes with RPMI-supplemented medium. CFSE-labeled
target T cells and autologous or allogeneic DCs were cultured in a
round-bottom well of a 96 well plate, in the presence of HIV
peptide KF11 (2-0.02 ng/ml), or SEB (10-0.001 ng/ml), or no
stimulant. Cells were collected, stained, and fixed with 1%
paraformaldehyde, and analyzed on day five post-activation.
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